ADVANCES IN TUMOR MARKERS FOR THE EARLY DIAGNOSIS OF PAPILLARY THYROID CARCINOMA

Papillary Thyroid Carcinoma (PTC) is a common endocrine malignancy and mostly is found in women. Different pathological types of PTC have different biological behaviors. The hidden onset results in difficulties to diagnose the early PTC. With the development of the molecular biology, increasing the number of researchers is a focus on tumor markers. The sensitivity and specificity of these tumor markers are helpful for early diagnosis and therapy of PTC. This review is oriented towards the finding of the potent thyroid cancer markers have enhanced sensitivity and specificity, with diagnostic, prognostic and therapeutic efficiency.

• Publication year

  2016

• Venue

  International Journal of Pharmacy and Pharmaceutical Sciences

• Publication date

  2016-09-17

• Fields of study

  Medicine

• Identifiers
  DOI 10.22159/ijpps.2016v8s2.15221
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar

• No claims are published for this paper.

• No concepts are published for this paper.

• Decreased expression of p27 is associated with malignant transformation and extrathyroidal extension in papillary thyroid carcinoma

  2016cited by this paper
• The RET oncogene in papillary thyroid carcinoma

  2015influential reference
• Significance of CK19, TPO, and HBME-1 expression for diagnosis of papillary thyroid carcinoma.

  2015cited by this paper
• VEGF Trapon inhibits tumor growth in papillary thyroid carcinoma.

  2015influential reference
• Is BECLIN-1 Immunoreactivity More Effective than HBME-1 in Diagnosis of Papillary Thyroid Cancer ?

  2015cited by this paper
• Tumor genotype determines phenotype and disease-related outcomes in thyroid cancer: a study of 1510 patients.

  2015cited by this paper
• [Expression of EpCAM and E-cadherin in papillary thyroid carcinoma and its clinicopathologic significance].

  2015cited by this paper
• Strong Expression of HBME-1 Associates with High-Risk Clinicopathological Factors of Papillary Thyroid Carcinoma

  2015cited by this paper
• Treatment related morbidity in differentiated thyroid cancer–a survey of clinicians

  2014cited by this paper
• Expression of papillary thyroid carcinoma-associated molecular markers and their significance in follicular epithelial dysplasia with papillary thyroid carcinoma-like nuclear alterations in Hashimoto's thyroiditis.

  2014influential reference
• Projecting cancer incidence and deaths to 2030: the unexpected burden of thyroid, liver, and pancreas cancers in the United States.

  2014cited by this paper
• Annual Report to the Nation on the status of cancer, 1975‐2010, featuring prevalence of comorbidity and impact on survival among persons with lung, colorectal, breast, or prostate cancer

  2014cited by this paper
• [The expression and significance of trefoil factor 3 and SDF-1/CXCR4 biological axis in papillary thyroid carcinoma].

  2014cited by this paper
• Differential expression patterns and clinical significance of estrogen receptor-α and β in papillary thyroid carcinoma

  2014cited by this paper
• The value of tumor markers in the diagnosis of papillary thyroid carcinoma alone and in combination.

  2014cited by this paper
• Enhanced activation of matrix metalloproteinase-9 correlates with the degree of papillary thyroid carcinoma infiltration

  2014influential reference
• Cytokeratin19 expression discriminates papillary thyroid carcinoma from other thyroid lesions and predicts its aggressive behavior

  2013cited by this paper
• [Detection of galectin-3 in both serum and tissue for early diagnosis of thyroid carcinoma].

  2013cited by this paper
• Expression of MMP-13 is associated with invasion and metastasis of papillary thyroid carcinoma.

  2013influential reference
• Combined staining for immunohistochemical markers in the diagnosis of papillary thyroid carcinoma: Improvement in the sensitivity or specificity?

  2013cited by this paper
• Galectin‐3 expression in thyroid fine needle cytology (t‐FNAC) uncertain cases: Validation of molecular markers and technology innovation

  2013cited by this paper
• [Expression and clinical significance of Muc1, p63 protein in diffuse sclerosing variant of papillary thyroid carcinoma and conventional papillary thyroid carcinoma].

  2013cited by this paper
• Expression of ck-19, galectin-3 and hbme-1 in the differentiation of thyroid lesions: systematic review and diagnostic meta-analysis

  2012cited by this paper
• Neutrophil gelatinase-associated lipocalin (NGAL) immunohistochemical expression in follicular cell-derived thyroid tumors: a novel diagnostic tool?

  2012influential reference
• Early death from papillary thyroid carcinoma.

  2012cited by this paper
• Cytokeratin 19 immunoreactivity in the diagnosis of papillary thyroid carcinoma

  2012cited by this paper
• Diagnostic significance of CK19, TG, Ki67 and galectin-3 expression for papillary thyroid carcinoma in the northeastern region of China

  2011cited by this paper
• A critical look on condoms.

  2010cited by this paper
• Minichromosome maintenance protein 3 is a candidate proliferation marker in papillary thyroid carcinoma.

  2010cited by this paper
• Thyroid cancer epidemiology and prognostic variables.

  2010cited by this paper
• Future of cancer incidence in the United States: burdens upon an aging, changing nation.

  2009cited by this paper
• Expression of galectin-3, cytokeratin 19, neural cell adhesion molecule and E-cadhedrin in certain variants of papillary thyroid carcinoma.

  2008cited by this paper
• Identification of immunohistochemical biomarkers for papillary thyroid carcinoma using gene expression profiling.

  2008cited by this paper
• Galectin-3-expression analysis in the surgical selection of follicular thyroid nodules with indeterminate fine-needle aspiration cytology: a prospective multicentre study.

  2008cited by this paper
• Targeted molecular therapy of anaplastic thyroid carcinoma with AEE788

  2005cited by this paper
• Hashimoto's thyroiditis with papillary thyroid carcinoma (PTC)‐like nuclear alterations express molecular markers of PTC

  2004cited by this paper
• Cancer statistics

  1989cited by this paper

• ESTIMATION OF ENTRANCE SURFACE RADIATION DOSE TO THYROID REGION IN COMPUTED TOMOGRAPHY BRAIN EXAMINATION

  2019cites this paper
• Diagnostic value of fine-needle aspiration combined with ultrasound for thyroid cancer

  2019cites this paper